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Abstract
Cardiovascular disease is the major cause of death in chronic kidney disease (CKD) patients. The
main underlying reason is inflammation. In CKD, interleukin-6 and hypersensitive C-reactive
protein are known to be used for the evaluation of inflammation and serum levels increase with
decreased creatinine clearance. Neutrophil gelatinase-associated lipocalin (NGAL) and hepcidin
are also considered to be effective in the assessment of inflammatory conditions. The possible
interactions of NGAL and hepcidin with inflammatory markers in CKD patients including the
kidney transplants, which have not been thoroughly explained up to date wereevaluated in this
study. Serum creatinine, iron, unsaturated iron binding capacity, interleukin-6, hypersensitive
C-reactive protein, NGAL, hepcidin and pro-hepcidin levels were measured in a cohort of 163
CKD patients including transplant patients and 82 healthy volunteers. Clinical evaluation and
classification of the patients were done according to the NFK/KDOQI guideline. Serum hepcidin,
Prohepcidin, NGAL, hypersensitive C-reactive protein and interleukin-6 levels were higher in
patient groups compared to the control group. In patient groups, while hepcidin, NGAL,
interleukin-6, hypersensitive C-reactive protein levels were correlated with creatinine and
glomerular filtration rate, iron metabolism parameters were not correlated with the
inflammation biomarkers. Inflammation related hepcidin and NGAL weakly correlated with
creatinine clearance. Our results demonstrated that serum NGAL and hepcidin levels might be
valuable for the evaluation of inflammation in CKD, and these new inflammation parameters
are not related through iron metabolism.
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Introduction
Chronic kidney disease (CKD) is a general term for hetero-
geneous disorders affecting kidney structure and functions1
and is a major worldwide public health problem in which
factors such as diabetes, hypertension, autoimmune diseases,
urinary stones, drug toxicity directly initiate kidney damage.2
The most serious outcome of CKD is considered as kidney
failure. In these cases, severely decreased kidney function
results with complications and treatment can be achieved only
by dialysis or transplantation.1 In CKD, irreversible abnorm-
alities in kidney structure (damage) are due to ischemic, toxic
or metabolic damage.3 According to KDIGO 2012 Clinical
Practice Guideline for the Evaluation and Management of
Chronic Kidney Disease, because of the graft failure and
repression of immunity caused by the drugs used after
transplantation, kidney transplant recipients are considered as
CKD patients.1,2
The major cause of mortality in CKD patients is cardio-
vascular disease.2 The complications seen in these patients are
the results of uremia, oxidative stress and fluid overload,
which are based on inflammation. Inflammation increases
directly related with the progression of the disease starting
from the initiation of the disease.1,4 Inflammatory markers hs-
CRP and IL-6 are known to be valuable in the evaluation of
inflammation4,5 and serum IL-6 levels increase depending on
the reduction of renal function.4,6 In addition to the known
inflammation markers, neutrophil gelatinase-associated lipo-
calin (NGAL) and hepcidin are considered to be effective in
the assessment of inflammatory conditions.7 NGAL also
known as lipocalin-2 (lcn 2) is a 25-kDa transporter belonging
to the lipocalin superfamily8,9 contains 178 amino acids.10
NGAL is expressed and secreted by immune cells, hepato-
cytes and renal tubular cells in various pathologic states.
NGAL exerts bacteriostatic effects by capturing and depleting
small iron binding molecules ‘‘siderophores’’ that are
synthesized by certain bacteria.9 NGAL can be freely filtrated
through glomerulus and reabsorbed from proximal tubules.11
It has been reported that serum levels of NGAL increase in
acute and chronic renal failure.9,10
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Hepcidin is a peptid hormone that was discovered simul-
taneously as an antibacterial protein found in human urine and
as a protein preferentially expressed in iron-loaded murine
liver. This is a circulating antimicrobial peptide mainly
synthesized in the liver, which has been recently proposed
as a factor regulating the uptake of dietary iron and its
mobilization from macrophages and hepatic stores. Hepcidin
was also considered as an acute phase protein.12 Hepcidin
synthesis is induced by IL-6.13,14
The role of NGAL and hepcidin in inflammation is also a
matter of debate whether they act through the loss of renal
function, iron metabolism or another mechanism.7 There are
very few studies investigating the interactions between NGAL
and hepcidin in CKD patients. However, to the best of our
knowledge, there is no data on this interaction in CKD
patients including transplant patients. Our study is based on




The study protocol was approved by the institutional ethical
committee and a written informed consent was obtained from
the recipients before the enrollment.
Between February and June 2012, a total of 163 patients
stages I–V CKD, diagnosed in the last 5 years in Pamukkale
University Hospital, were included to the study. Eighty-one of
them were without dialysis treatment (43 males, 38 females,
18–75 years) and 82 were treated with kidney transplantation
(44 males, 38 females, 18–75 years).
Clinical evaluation and classification of the patients with
CKD were done according to the NFK/KDOQI guideline.1,2
Control group was consisted of 82 healthy known individuals
without malignancy, active infection, chronic/metabolic dis-
ease and diabetes.
Samples and the measurement of the parameters
Fasting venous blood samples were collected in the morning
and 24 h urine collection was demanded from all the
participants. Serum obtained by the centrifugation of the
blood samples was aliquated and stored in20 C until
serum NGAL, IL-6, hepcidin and pro-hepcidin levels was
measured. Serum hs-CRP, iron, UIBC, creatinine and urine
creatinine levels were measured the same day the samples
obtained.
Serum creatinine, iron, unsaturated iron binding capacity
(UIBC) and urine creatinine levels were measured by using
colorimetric, hsCRP immunoturbidimetric on a Cobas 6000
autoanalyzer (Roche Diagnostics, Tokyo, Japan). Serum
NGAL (Biovendor, Czech Republic), IL-6 (eBioscience,
Austria), hepcidin (DRG, Germany) and pro-hepcidin
(DRG) levels were measured by using commercial kits
according to the manufacturer’s instructions. All these four
parameters were measured by enzyme-linked immunosorbent
method.
Total iron binding capacity (TIBC) was calculated as the
total of serum iron and UIBC. TIBC is used in calculation of
% transferrin saturation. Transferrin saturation (%)
was calculated as the rate of iron level to the TIBC
(Tfr sat¼ (serum iron level 100)/TIBC) and referents
intervals are as 15–45%.
Creatinine clearance (GFR) was calculated by the formula:
24 h urine vol/1440 serum creatinine level. Referent values
are 88–128 mL/min (female) and 97–137 mL/min (male).1,2
Statistical analysis
SPSS software, version 17.0 (SPSS, Chicago, IL) was used for
statistical analyses. The distribution of continuous variables
was analyzed using the Kolmogorov–Smirnov test, in order to
assess significant departures from normality and for homo-
genicity of variants Levene test was used. For non-normally
distributed parameters, results were presented as median
(interquartile range).
For samples with normal distribution statistical analysis for
the differences between patient group (CKD + transplanted
group) and the control group were performed with t-test and
expressed as mean ± SD.
For samples with skewed distribution statistical analysis for
the differences between patient group (CKD + transplanted
group) and the control group were performed with Mann–
Whitney U test and expressed as median (interquartile range).
Whenever the parameters presented normal distribution
multiple comparisons between groups were performed by
one-way ANOVA. For analysis of variance Kruskal–Wallis
test was used for samples with skewed distribution.
Correlations were evaluated by correlation and multiple
regression analyses where appropriate (y¼ ax+b). In all three
groups, while the distributions are non-parametric and study
groups are small spearmen correlation analyses was per-
formed and CKD and renal transplant groups are considered
as one group. In correlation analysis, rho (spearmen correl-
ation coefficient) values are accepted as 0.000–0.49 weak
correlation, 0.50–0.69 moderate correlation,0.70 strong
correlation. For the other statistical analyses, significance
was accepted at p less than 0.05.
Results
All the variables of the groups are given in Table 1. CKD
compared to the control group had significantly higher hs-
CRP levels (p¼ 0.000), whereas renal transplant group
compared to the control group and CKD group compared to
the transplant group there were no significant differences
(p¼ 0.052, p¼ 0.107, respectively). Significant differences
were determined in terms of hepcidin between all groups
(p¼ 0.000). In terms of Prohepcidin, while there was a
significant difference between control group and both CKD
and renal transplant group (p¼ 0.000, p¼ 0.000 respectively),
no significant difference was determined between CKD and
renal transplant group (p¼ 1.000). Serum IL-6 and NGAL
levels were significantly different between all three groups
(p¼ 0.000).
In CKD group, as the patients were under iron replacement
therapy, there was no significant difference among control
and patient groups in Tfr sat (p¼ 0.107). No significant
differences were detected among control and CKD group in
regard to BMI (p¼ 0.766) and age (p¼ 0.182), control and
renal transplant group in regard to hs-CRP (p¼ 0.052) and
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iron (p¼ 0.973), CKD and renal transplant group in regard to
hs-CRP (p¼ 0.107), UIBC (p¼ 0.149) and Prohepcidin
(p¼ 1.000).
In Table 2, correlations among inflammation parameters
and iron, UIBC, TIBC, Tfr sat, in Table 3 correlations among
inflammation parameters and renal function markers in
patient groups were given.
In our study, we did not establish any correlation between
markers of inflammation and both renal function and iron
status indicators in healthy participants.
Discussion
Inflammation is the most important underlying mechanism in
cardiovascular disease and other systemic diseases, which are
the major causes of morbidity and mortality in chronic renal
failure1,15
In chronic renal disease, the toxicity caused by increased
oxidative stress, decreased cytokine clearance, chronic infec-
tions, hypertension, fluid overload, metabolic dysfunction
(hyperglycemia) and uremia induce some signal pathways
which results with increased serum IL-6 level. Increased IL-6
leads to chronic inflammatory conditions such as the synthe-
sis of acute phase proteins like CRP, hypercoagulability and
accelerated atherosclerosis.16,17 In our study, we demon-
strated that serum IL-6 level is highly related with the kidney
function parameters compared to hsCRP level. This result
might suggest that IL-6 is the main contributor in chronic
inflammation and is related with the loss of renal function.
Serum hsCRP level of the CKD group was significantly
(p¼ 0.000) higher than the control group, that might support
the concept of higher risk of morbidity and mortality from
CVD in CKD patients. There was a negative correlation in
serum hsCRP, IL-6 levels with GFR in both CKD and renal
transplant patients in our study. Serum IL-6 showed a stronger
relation with the renal function parameters (serum creatinine
level, GFR) than hsCRP level. These results support those
inflammation parameters in serum increase depending on the
decrease of the creatinine clearance or the loss of renal
function.
Hepcidin’s molecular structure and control mechanisms
are better understood by the studies done in the last 5 years,
and is clearly demonstrated that hepcidin is the basic regulator
of systemic iron metabolism.7,14,18 Hepcidin is eliminated
from the body through the kidneys.7 During inflammation and
infections, hepcidin level increases and extracellular iron
levels decrease leading to the inhibition of iron acquisition,
which is essential necessary for the microorganisms.14 Studies
since the discovery of hepcidin are generally conducted in
animals and in vitro experiments.19 Small and compact
peptide structure, the tight integration between components
and antigen-compatibility of hepcidin is hindering factors for
development of a suitable immunochemical method.20 For
this reason, many clinical trials are carried out with
Table 1. Clinical and biochemical features of the study groups.
Variable Control (n¼ 81) CKD (n¼ 81) Renal transplant (n¼ 82)
Age (years) 46.73 ± 10.50f 50.29 ± 15.68h 41.79 ± 11.66
BMI (kg/cm2) 23.33 ± 0.24d 23.11 ± 0.22i 24.22 ± 0.22
Creatinine (mg/dL) 0.74 (0.25)a,g 2.47 (0.90)h 1.01 (0.10)
GFR (mL/min) 108.79 (29.62)a,c 36.6 (29)h 55.94 (35.10)
Iron (mg/dL) 89.49 ± 33.17b 68.53 ± 28.53h 90.76 ± 45.37
UIBC (mg/dL) 245 (98.2)a,e 188.5 (91.3) 212 (114.6)
TIBC (mg/dL) 345.53 ± 62.12a,c 262.74 ± 41.90h 308.12 ± 65.04
Tfr sat (%) 27.34 ± 12.20 27.24 ± 12.49 31.64 ± 19.40
hs-CRP (mg/L) 1.02 (1.06)a 3.94 (7.46) 1.61 (3.81)
IL-6 (pg/mL) 1.75 (1.88)a,c 48.6 (27.52)h 10.33 (4.64)
Hepcidin (ng/mL) 3.28 (5.12)a,c 81 (53.03)h 30.18 (14.57)
Pro-hepcidin (ng/mL) 43.65 (7.04)a,c 773.72 (536.07) 581.4 (490.95)
NGAL (ng/mL) 1.66 (1.15)a,c 4.01 (1.32)h 2.96 (1.96)










Difference between CKD and renal transplant groups
hp¼ 0.000,
ip¼ 0.018.
Table 2. Correlations among inflammation parameters and iron, UIBC,
TIBC, Tfr sat in patient group.
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Prohepcidin consisting of 60 aa, which is the precursor
protein of hepcidin although biological relation and relevance
of Prohepcidin with hepcidin is not clear20 and Prohepcidin is
now believed to be poor marker of hepcidin bioactivity.14
Prohepcidin levels differ by stimulation of inflammation
rather than changes in iron metabolism.19,21 Due to the
technical problems and roles of both Prohepcidin and
hepcidin in inflammation course and control of iron metab-
olism, additionally the determination of Prohepcidin is
important for providing information for the evaluation of
inflammation.21
In our study, because of the above-mentioned reasons in
addition to serum hepcidin level, serum prohepcidin level was
also measured and no significant correlation was determined
among them. This finding supports the weak biological
relationship between each other. The weak correlation of
Prohepcidin with both iron parameters and cytokines in
patient groups suggests that it may not be an advantageous
biomarker in clinical surveillance and researches.
While hepcidin levels were found to be significantly
different in all groups, Prohepcidin levels were higher in CKD
group compared to control and renal transplant groups and not
significantly different in CKD and renal transplant groups The
increase in serum hepcidin level in CKD group compared to
control group might be a result of not only the increased
production due to inflammation, but also to the participation
of kidneys in elimination of hepcidin as suggested by
Kulaks{z et al.22 In CKD group depending on the damage
of kidney, the elimination of hepcidin is limited and results
with the increase in serum level.
In our study, another inflammation parameter NGAL was
found to be negatively correlated with iron. It can be
suggested that this correlation is a result of NGAL binding
small iron binding molecules and load the cell with iron23
demonstrating the importance of iron load during bacterial
infections and kidney damage. It was stated that in various
pathologic conditions NGAL expressed in immune cells and
secreted limits tubular injury and which is an independent
affect from its bacteriostatic action. NGAL is also accepted as
modulating various cellular responses, such as proliferation,
apoptosis and differentiation with an unknown mechan-
ism.9,23,24 Recent studies demonstrate the involvement of
NGAL in adaptive stage of CKD.7 It was hypothesized that in
CKD, the change in the physiology of this protein is
comparable to the acute injury. Chronic injured kidney
tubules produce enhanced NGAL. In conclusion, increased
NGAL level is not only a result of decreased clearance, but
also increased production.14
In our study, serum NGAL levels are significantly different
when compared in all groups. CKD group has the highest
mean level of NGAL. This result indicates that chronic
injury might enhance the production and/or reduce the
clearance of NGAL. Increased serum NGAL level in renal
transplant group compared to healthy group might be due to
toxic injury caused by the calcineurin inhibitors used.25
NGAL positively correlated with serum creatinine levels in
patient groups is an evidence for association with the
elimination. There are other studies also demonstrating the
correlation of NGAL with creatinine levels in CKD patients
with higher levels than the controls.26 Both NGAL and
hepcidin possessing antimicrobial effects are acute phase
proteins, which are related with inflammation and restrict iron
uptake and usage. While NGAL express this activity by
stimulating the synthesis of iron binding proteins (transferrin),
decreasing the absorption of dietary iron and enhancing the
iron storing protein levels, hepcidin an antibacterial defensin
induced in the liver as a response to IL-6 stimulation,
expresses by decreasing the absorption of dietary iron and
preventing iron release from macrophages.7,14,19
In our study, hepcidin and NGAL, regulator in iron
metabolism and inducing kidney injury along with inflam-
mation were demonstrated to be related with the kidney
function parameters. The negative correlation of these
parameters with GFR supports the estimate that these
parameters might reflect the progression of inflammation in
CKD.26 In conclusion, the relation of both serum NGAL and
hepcidin levels with the inflammatory parameters and renal
function indicators supports the point of view that both
parameters are effective in inflammation possibly by similar
mechanisms.
Depending on the correlations the relation of the inflam-
matory parameters with the renal function indicators is more
prominent than the relations with the iron metabolism
parameters. Also, the correlation of GFR related IL-6 with
hepcidin and NGAL is also an evidence for the relevance with
inflammation in CKD.
According to our results, we conclude that serum hepcidin,
Prohepcidin and NGAL levels can be used for the evaluation
of inflammation in CKD patients including renal transplant
patients together with the serum IL-6 and hsCRP levels. The
data of our study can be used as preliminary information in
the new studies regarding hepcidin and NGAL related with
inflammation in CKD patients including the renal transplant
patients.
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